Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2

Abstract Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.

Authors

Institutions

Publication Details

Journal
ACS Nano
Published
2026-11-12
DOI
https://doi.org/10.1021/acsnano.6c13208
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2

张玉云, Hai Yu, Ting Wu, Wenhui Xue et al.
ACS Nano
SARS-CoV-2 and COVID-19 Research
article

Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2

张玉云, Hai Yu, Ting Wu, Wenhui Xue, 刘宏景, Lunzhi Yuan, Ningshao Xia, Miaolin Lan, Zihao Chen, Ming Zhou, Shaowei Li, Yarong Zeng, Lingyan Cui, Jinjin Li, Hai Li, Ying Gu, Longmei Zhang, Sibo Zhang, Yali Zhang, Lin Chen, Jian Ma, Hong Wang, Kun Wu, Tingting Li, Jin Xiao
article en

Abstract

Abstract Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.

ACS Nano
Xiamen University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Fujian Province, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon